Publicacións (13) Publicacións de David Arias Ron

2022

  1. Parkinson's disease and diabetes mellitus: Common mechanisms and treatment repurposing

    Neural Regeneration Research, Vol. 17, Núm. 8, pp. 1652-1658

2021

  1. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists

    Frontiers in Neuroendocrinology, Vol. 62

  2. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  3. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

2020

  1. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1205-1215

  2. Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report

    Case Reports in Oncology, Vol. 13, Núm. 1, pp. 69-75

2019

  1. Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

    Frontiers in Oncology, Vol. 9

  2. Is there room for personalized medicine in Small-Cell Lung Cancer (SCLC)? Remarkable activity of pazopanib in refractory FGFR1-amplified ED-SCLC

    JCO Precision Oncology, Vol. 3, pp. 1-8

  3. Tratamiento perioperatorio en cáncer de vejiga: Revisión de la literatura

    Revisiones en Cancer, Vol. 33, Núm. 5, pp. 210-215

2018

  1. Challenges in lung cancer screening in Latin America

    Journal of Global Oncology, Vol. 2018, Núm. 4

  2. Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii225

  3. Epidemiología y factores pronósticos de los tumores neuroendocrinos

    Revisiones en Cancer, Vol. 32, Núm. 5, pp. 287-293

  4. Indications for locoregional tumor therapies: CRC liver metastases

    Locoregional Tumor Therapy (Springer International Publishing), pp. 83-106